Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Sponsor
Shi Ming
Study ID
NCT05760599
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Candonilimab — DRUG
    10mg/kg, iv.drip, every 3 week
  • Bevacizumab — DRUG
    15mg/kg, iv.drip, every 3 week

Study Details

To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Key Dates

First listed
Mar 8, 2023
Start date
Feb 27, 2023
Status verified
Feb 2023
Primary completion
Jan 1, 2024
Completion
Jul 1, 2024

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Candonilimab Plus Bevacizumab
    Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week

Primary Outcome Measure

DCR per RECIST 1.1 [ Time Frame: 12 months ]

Related Studies